Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Treg-mediated prolonged survival of skin allografts without immunosuppression.

Pilat N, Wiletel M, Weijler AM, Steiner R, Mahr B, Warren J, Corpuz TM, Wekerle T, Webster KE, Sprent J.

Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13508-13516. doi: 10.1073/pnas.1903165116. Epub 2019 Jun 13.

PMID:
31196957
2.

Hybrid resistance to parental bone marrow grafts in nonlethally irradiated mice.

Mahr B, Pilat N, Granofszky N, Wiletel M, Muckenhuber M, Maschke S, Hock K, Wekerle T.

Am J Transplant. 2019 Feb;19(2):591-596. doi: 10.1111/ajt.15146. Epub 2018 Nov 16.

3.

CTLA4Ig Improves Murine iTreg Induction via TGFβ and Suppressor Function In Vitro.

Pilat N, Mahr B, Gattringer M, Baranyi U, Wekerle T.

J Immunol Res. 2018 Jul 2;2018:2484825. doi: 10.1155/2018/2484825. eCollection 2018.

4.

Allograft rejection is associated with development of functional IgE specific for donor MHC antigens.

Farkas AM, Baranyi U, Böhmig GA, Unger L, Hopf S, Wahrmann M, Regele H, Mahr B, Schwarz C, Hock K, Pilat N, Kristo I, Mraz J, Lupinek C, Thalhamer J, Bond G, Kuessel L, Wlodek E, Martin J, Clatworthy M, Pettigrew G, Valenta R, Wekerle T.

J Allergy Clin Immunol. 2019 Jan;143(1):335-345.e12. doi: 10.1016/j.jaci.2018.06.034. Epub 2018 Aug 9.

5.

Blockade of adhesion molecule lymphocyte function-associated antigen-1 improves long-term heart allograft survival in mixed chimeras.

Pilat N, Sabler P, Klaus C, Mahr B, Unger L, Hock K, Wiletel M, Schwarz C, Kristo I, Regele H, Wekerle T.

J Heart Lung Transplant. 2018 Sep;37(9):1119-1130. doi: 10.1016/j.healun.2018.03.016. Epub 2018 Mar 30.

PMID:
29699851
6.

Combining Adoptive Treg Transfer with Bone Marrow Transplantation for Transplantation Tolerance.

Pilat N, Granofszky N, Wekerle T.

Curr Transplant Rep. 2017;4(4):253-261. doi: 10.1007/s40472-017-0164-7. Epub 2017 Nov 4. Review.

7.

Anti-Interleukin-6 Promotes Allogeneic Bone Marrow Engraftment and Prolonged Graft Survival in an Irradiation-Free Murine Transplant Model.

Granofszky N, Farkas AM, Muckenhuber M, Mahr B, Unger L, Maschke S, Pilat N, Holly R, Wiletel M, Regele H, Wekerle T.

Front Immunol. 2017 Jul 19;8:821. doi: 10.3389/fimmu.2017.00821. eCollection 2017.

8.

Regulatory T Cells Promote Natural Killer Cell Education in Mixed Chimeras.

Mahr B, Pilat N, Maschke S, Granofszky N, Schwarz C, Unger L, Hock K, Farkas AM, Klaus C, Regele H, Wekerle T.

Am J Transplant. 2017 Dec;17(12):3049-3059. doi: 10.1111/ajt.14342. Epub 2017 Jun 6.

9.

Minor Antigen Disparities Impede Induction of Long Lasting Chimerism and Tolerance through Bone Marrow Transplantation with Costimulation Blockade.

Bigenzahn S, Pree I, Klaus C, Pilat N, Mahr B, Schwaiger E, Nierlich P, Wrba F, Wekerle T.

J Immunol Res. 2016;2016:8635721. Epub 2016 Oct 31.

10.

Incomplete clonal deletion as prerequisite for tissue-specific minor antigen tolerization.

Pilat N, Mahr B, Unger L, Hock K, Schwarz C, Farkas AM, Baranyi U, Wrba F, Wekerle T.

JCI Insight. 2016 May 19;1(7):e85911. doi: 10.1172/jci.insight.85911.

11.

The Immunosuppressive Effect of CTLA4 Immunoglobulin Is Dependent on Regulatory T Cells at Low But Not High Doses.

Schwarz C, Unger L, Mahr B, Aumayr K, Regele H, Farkas AM, Hock K, Pilat N, Wekerle T.

Am J Transplant. 2016 Dec;16(12):3404-3415. doi: 10.1111/ajt.13872. Epub 2016 Jul 5.

12.

IL-2/α-IL-2 Complex Treatment Cannot Be Substituted for the Adoptive Transfer of Regulatory T cells to Promote Bone Marrow Engraftment.

Mahr B, Unger L, Hock K, Pilat N, Baranyi U, Schwarz C, Maschke S, Farkas AM, Wekerle T.

PLoS One. 2016 Jan 5;11(1):e0146245. doi: 10.1371/journal.pone.0146245. eCollection 2016.

13.

Anti-OX40L alone or in combination with anti-CD40L and CTLA4Ig does not inhibit the humoral and cellular response to a major grass pollen allergen.

Gattringer M, Baranyi U, Pilat N, Hock K, Klaus C, Ramsey HE, Wrba F, Valenta R, Wekerle T.

Clin Exp Allergy. 2016 Feb;46(2):354-64. doi: 10.1111/cea.12661.

14.

Polyclonal Recipient nTregs Are Superior to Donor or Third-Party Tregs in the Induction of Transplantation Tolerance.

Pilat N, Klaus C, Hock K, Baranyi U, Unger L, Mahr B, Farkas AM, Wrba F, Wekerle T.

J Immunol Res. 2015;2015:562935. doi: 10.1155/2015/562935. Epub 2015 Jul 27.

15.

Rapamycin and CTLA4Ig synergize to induce stable mixed chimerism without the need for CD40 blockade.

Pilat N, Klaus C, Schwarz C, Hock K, Oberhuber R, Schwaiger E, Gattringer M, Ramsey H, Baranyi U, Zelger B, Brandacher G, Wrba F, Wekerle T.

Am J Transplant. 2015 Jun;15(6):1568-79. doi: 10.1111/ajt.13154. Epub 2015 Mar 17.

16.

Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: a p53 Research Group study.

Pilat N, Grünberger T, Längle F, Mittlböck M, Perisanidis B, Kappel S, Wolf B, Starlinger P, Kührer I, Mühlbacher F, Kandioler D.

Eur J Surg Oncol. 2015 May;41(5):683-9. doi: 10.1016/j.ejso.2015.02.003. Epub 2015 Feb 25.

PMID:
25773284
17.

Donor CD4 T cells trigger costimulation blockade-resistant donor bone marrow rejection through bystander activation requiring IL-6.

Hock K, Pilat N, Baranyi U, Mahr B, Gattringer M, Klaus C, Wekerle T.

Am J Transplant. 2014 Sep;14(9):2011-22. doi: 10.1111/ajt.12823. Epub 2014 Aug 6.

18.

T-regulatory cell treatment prevents chronic rejection of heart allografts in a murine mixed chimerism model.

Pilat N, Farkas AM, Mahr B, Schwarz C, Unger L, Hock K, Oberhuber R, Aumayr K, Wrba F, Wekerle T.

J Heart Lung Transplant. 2014 Apr;33(4):429-37. doi: 10.1016/j.healun.2013.11.004. Epub 2013 Nov 28.

19.

Implication for bone marrow derived stem cells in hepatocyte regeneration after orthotopic liver transplantation.

Pilat N, Unger L, Berlakovich GA.

Int J Hepatol. 2013;2013:310612. doi: 10.1155/2013/310612. Epub 2013 Sep 10. Review.

20.

The site of allergen expression in hematopoietic cells determines the degree and quality of tolerance induced through molecular chimerism.

Baranyi U, Gattringer M, Farkas AM, Hock K, Pilat N, Iacomini J, Valenta R, Wekerle T.

Eur J Immunol. 2013 Sep;43(9):2451-60. doi: 10.1002/eji.201243277. Epub 2013 Jul 15.

21.

Engraftment of retrovirally transduced Bet v 1-GFP expressing bone marrow cells leads to allergen-specific tolerance.

Gattringer M, Baranyi U, Pilat N, Hock K, Klaus C, Buchberger E, Ramsey H, Iacomini J, Valenta R, Wekerle T.

Immunobiology. 2013 Sep;218(9):1139-46. doi: 10.1016/j.imbio.2013.03.007. Epub 2013 Mar 30.

22.

CTLA4-Ig immunosuppressive activity at the level of dendritic cell/T cell crosstalk.

Mayer E, Hölzl M, Ahmadi S, Dillinger B, Pilat N, Fuchs D, Wekerle T, Heitger A.

Int Immunopharmacol. 2013 Mar;15(3):638-45. doi: 10.1016/j.intimp.2013.02.007. Epub 2013 Feb 20.

23.

Anti-LFA-1 or rapamycin overcome costimulation blockade-resistant rejection in sensitized bone marrow recipients.

Ramsey H, Pilat N, Hock K, Klaus C, Unger L, Schwarz C, Baranyi U, Gattringer M, Schwaiger E, Wrba F, Wekerle T.

Transpl Int. 2013 Feb;26(2):206-18. doi: 10.1111/tri.12021. Epub 2012 Dec 13.

24.

No evidence for recipient-derived hepatocytes in serial biopsies of sex-mismatched liver transplants.

Pilat N, Schoppmann S, Stift J, Mazal P, Wekerle T, Berlakovich GA.

Transplantation. 2012 Nov 15;94(9):953-7. doi: 10.1097/TP.0b013e318269e68d.

PMID:
23034562
25.

Persistent molecular microchimerism induces long-term tolerance towards a clinically relevant respiratory allergen.

Baranyi U, Pilat N, Gattringer M, Linhart B, Klaus C, Schwaiger E, Iacomini J, Valenta R, Wekerle T.

Clin Exp Allergy. 2012 Aug;42(8):1282-92. doi: 10.1111/j.1365-2222.2012.04049.x.

26.

Modulating T-cell costimulation as new immunosuppressive concept in organ transplantation.

Pilat N, Schwarz C, Wekerle T.

Curr Opin Organ Transplant. 2012 Aug;17(4):368-75. doi: 10.1097/MOT.0b013e328355fc94. Review.

PMID:
22790071
27.

Belatacept and Tregs: friends or foes?

Pilat N, Wekerle T.

Immunotherapy. 2012 Apr;4(4):351-4. doi: 10.2217/imt.12.13. No abstract available.

PMID:
22512625
28.

Mixed chimerism through donor bone marrow transplantation: a tolerogenic cell therapy for application in organ transplantation.

Pilat N, Hock K, Wekerle T.

Curr Opin Organ Transplant. 2012 Feb;17(1):63-70. doi: 10.1097/MOT.0b013e32834ee68b. Review.

PMID:
22186093
29.

IDO and regulatory T cell support are critical for cytotoxic T lymphocyte-associated Ag-4 Ig-mediated long-term solid organ allograft survival.

Sucher R, Fischler K, Oberhuber R, Kronberger I, Margreiter C, Ollinger R, Schneeberger S, Fuchs D, Werner ER, Watschinger K, Zelger B, Tellides G, Pilat N, Pratschke J, Margreiter R, Wekerle T, Brandacher G.

J Immunol. 2012 Jan 1;188(1):37-46. doi: 10.4049/jimmunol.1002777. Epub 2011 Nov 30.

30.

Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative conditioning.

Schwaiger E, Klaus C, Matheeussen V, Baranyi U, Pilat N, Ramsey H, Korom S, De Meester I, Wekerle T.

Exp Hematol. 2012 Feb;40(2):97-106. doi: 10.1016/j.exphem.2011.10.010. Epub 2011 Nov 13.

31.

Therapeutic efficacy of polyclonal tregs does not require rapamycin in a low-dose irradiation bone marrow transplantation model.

Pilat N, Klaus C, Gattringer M, Jaeckel E, Wrba F, Golshayan D, Baranyi U, Wekerle T.

Transplantation. 2011 Aug 15;92(3):280-8. doi: 10.1097/TP.0b013e3182241133.

PMID:
21697774
32.

Costimulatory pathways in transplantation.

Pilat N, Sayegh MH, Wekerle T.

Semin Immunol. 2011 Aug;23(4):293-303. doi: 10.1016/j.smim.2011.04.002. Epub 2011 May 26.

33.

Combining Treg therapy with mixed chimerism: Getting the best of both worlds.

Pilat N, Wekerle T.

Chimerism. 2010 Jul-Sep;1(1):26-9. doi: 10.4161/chim.1.1.12964.

34.

Mechanistic and therapeutic role of regulatory T cells in tolerance through mixed chimerism.

Pilat N, Wekerle T.

Curr Opin Organ Transplant. 2010 Dec;15(6):725-30. doi: 10.1097/MOT.0b013e3283401755. Review.

PMID:
20881493
35.

Transplantation tolerance through mixed chimerism.

Pilat N, Wekerle T.

Nat Rev Nephrol. 2010 Oct;6(10):594-605. doi: 10.1038/nrneph.2010.110. Epub 2010 Aug 31. Review.

PMID:
20808286
36.

The role of natural killer T cells in costimulation blockade-based mixed chimerism.

Nierlich PN, Klaus C, Bigenzahn S, Pilat N, Koporc Z, Pree I, Baranyi U, Taniguchi M, Muehlbacher F, Wekerle T.

Transpl Int. 2010 Nov;23(11):1179-89. doi: 10.1111/j.1432-2277.2010.01120.x.

37.

Treg-therapy allows mixed chimerism and transplantation tolerance without cytoreductive conditioning.

Pilat N, Baranyi U, Klaus C, Jaeckel E, Mpofu N, Wrba F, Golshayan D, Muehlbacher F, Wekerle T.

Am J Transplant. 2010 Apr;10(4):751-62. doi: 10.1111/j.1600-6143.2010.03018.x. Epub 2010 Feb 10.

38.

A chimerism-based approach to induce tolerance in IgE-mediated allergy.

Baranyi U, Pilat N, Gattringer M, Wekerle T.

Crit Rev Immunol. 2009;29(5):379-97. Review.

PMID:
20001887
39.

Hurdles to the induction of tolerogenic mixed chimerism.

Pilat N, Klaus C, Schwaiger E, Wekerle T.

Transplantation. 2009 May 15;87(9 Suppl):S79-84. doi: 10.1097/TP.0b013e3181a2b9cc.

PMID:
19424016
40.

Bone marrow transplantation as a strategy for tolerance induction in the clinic.

Pree I, Pilat N, Wekerle T.

Front Biosci (Landmark Ed). 2009 Jan 1;14:611-20. Review.

PMID:
19273089
41.

Murine mobilized peripheral blood stem cells have a lower capacity than bone marrow to induce mixed chimerism and tolerance.

Koporc Z, Pilat N, Nierlich P, Blaha P, Bigenzahn S, Pree I, Selzer E, Sykes M, Muehlbacher F, Wekerle T.

Am J Transplant. 2008 Oct;8(10):2025-36. doi: 10.1111/j.1600-6143.2008.02371.x.

42.

Tolerization of a type I allergic immune response through transplantation of genetically modified hematopoietic stem cells.

Baranyi U, Linhart B, Pilat N, Gattringer M, Bagley J, Muehlbacher F, Iacomini J, Valenta R, Wekerle T.

J Immunol. 2008 Jun 15;180(12):8168-75.

43.

Recent progress in tolerance induction through mixed chimerism.

Pree I, Pilat N, Wekerle T.

Int Arch Allergy Immunol. 2007;144(3):254-66. Epub 2007 Jun 27. Review.

Supplemental Content

Support Center